Advertisement
ResearchIn-Press PreviewCell biologyOncology
Open Access | 10.1172/JCI180570
1Department of Molecular Medicine and Inflammation-Cancer Microenvironment R, College of Medicine, Ewha Womans University, Seoul, Korea, Republic of
2Deargen Inc., Daejeon, Korea, Republic of
3Department of Microbiology, College of Science & Technology, Dankook University, Cheonan, Korea, Republic of
4Research Institute and Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea, Republic of
5UroGyn Efficacy Evaluation Center, Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of
6Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by Lee, S. in: JCI | PubMed | Google Scholar
1Department of Molecular Medicine and Inflammation-Cancer Microenvironment R, College of Medicine, Ewha Womans University, Seoul, Korea, Republic of
2Deargen Inc., Daejeon, Korea, Republic of
3Department of Microbiology, College of Science & Technology, Dankook University, Cheonan, Korea, Republic of
4Research Institute and Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea, Republic of
5UroGyn Efficacy Evaluation Center, Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of
6Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by Park, J. in: JCI | PubMed | Google Scholar
1Department of Molecular Medicine and Inflammation-Cancer Microenvironment R, College of Medicine, Ewha Womans University, Seoul, Korea, Republic of
2Deargen Inc., Daejeon, Korea, Republic of
3Department of Microbiology, College of Science & Technology, Dankook University, Cheonan, Korea, Republic of
4Research Institute and Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea, Republic of
5UroGyn Efficacy Evaluation Center, Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of
6Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by Cho, S. in: JCI | PubMed | Google Scholar
1Department of Molecular Medicine and Inflammation-Cancer Microenvironment R, College of Medicine, Ewha Womans University, Seoul, Korea, Republic of
2Deargen Inc., Daejeon, Korea, Republic of
3Department of Microbiology, College of Science & Technology, Dankook University, Cheonan, Korea, Republic of
4Research Institute and Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea, Republic of
5UroGyn Efficacy Evaluation Center, Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of
6Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by Kim, E. in: JCI | PubMed | Google Scholar
1Department of Molecular Medicine and Inflammation-Cancer Microenvironment R, College of Medicine, Ewha Womans University, Seoul, Korea, Republic of
2Deargen Inc., Daejeon, Korea, Republic of
3Department of Microbiology, College of Science & Technology, Dankook University, Cheonan, Korea, Republic of
4Research Institute and Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea, Republic of
5UroGyn Efficacy Evaluation Center, Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of
6Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by Oh, S. in: JCI | PubMed | Google Scholar
1Department of Molecular Medicine and Inflammation-Cancer Microenvironment R, College of Medicine, Ewha Womans University, Seoul, Korea, Republic of
2Deargen Inc., Daejeon, Korea, Republic of
3Department of Microbiology, College of Science & Technology, Dankook University, Cheonan, Korea, Republic of
4Research Institute and Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea, Republic of
5UroGyn Efficacy Evaluation Center, Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of
6Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by Lee, Y. in: JCI | PubMed | Google Scholar
1Department of Molecular Medicine and Inflammation-Cancer Microenvironment R, College of Medicine, Ewha Womans University, Seoul, Korea, Republic of
2Deargen Inc., Daejeon, Korea, Republic of
3Department of Microbiology, College of Science & Technology, Dankook University, Cheonan, Korea, Republic of
4Research Institute and Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea, Republic of
5UroGyn Efficacy Evaluation Center, Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of
6Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by Park, S. in: JCI | PubMed | Google Scholar
1Department of Molecular Medicine and Inflammation-Cancer Microenvironment R, College of Medicine, Ewha Womans University, Seoul, Korea, Republic of
2Deargen Inc., Daejeon, Korea, Republic of
3Department of Microbiology, College of Science & Technology, Dankook University, Cheonan, Korea, Republic of
4Research Institute and Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea, Republic of
5UroGyn Efficacy Evaluation Center, Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of
6Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by Kang, K. in: JCI | PubMed | Google Scholar
1Department of Molecular Medicine and Inflammation-Cancer Microenvironment R, College of Medicine, Ewha Womans University, Seoul, Korea, Republic of
2Deargen Inc., Daejeon, Korea, Republic of
3Department of Microbiology, College of Science & Technology, Dankook University, Cheonan, Korea, Republic of
4Research Institute and Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea, Republic of
5UroGyn Efficacy Evaluation Center, Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of
6Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by
Shin, D.
in:
JCI
|
PubMed
|
Google Scholar
|
1Department of Molecular Medicine and Inflammation-Cancer Microenvironment R, College of Medicine, Ewha Womans University, Seoul, Korea, Republic of
2Deargen Inc., Daejeon, Korea, Republic of
3Department of Microbiology, College of Science & Technology, Dankook University, Cheonan, Korea, Republic of
4Research Institute and Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea, Republic of
5UroGyn Efficacy Evaluation Center, Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of
6Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by Ko, S. in: JCI | PubMed | Google Scholar
1Department of Molecular Medicine and Inflammation-Cancer Microenvironment R, College of Medicine, Ewha Womans University, Seoul, Korea, Republic of
2Deargen Inc., Daejeon, Korea, Republic of
3Department of Microbiology, College of Science & Technology, Dankook University, Cheonan, Korea, Republic of
4Research Institute and Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea, Republic of
5UroGyn Efficacy Evaluation Center, Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of
6Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by Kurie, J. in: JCI | PubMed | Google Scholar
1Department of Molecular Medicine and Inflammation-Cancer Microenvironment R, College of Medicine, Ewha Womans University, Seoul, Korea, Republic of
2Deargen Inc., Daejeon, Korea, Republic of
3Department of Microbiology, College of Science & Technology, Dankook University, Cheonan, Korea, Republic of
4Research Institute and Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea, Republic of
5UroGyn Efficacy Evaluation Center, Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of
6Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, United States of America
Find articles by
Ahn, Y.
in:
JCI
|
PubMed
|
Google Scholar
|
Published April 3, 2025 - More info
Hyaluronan (HA) in the extracellular matrix promotes epithelial-to-mesenchymal transition (EMT) and metastasis; however, the mechanism by which the HA network constructed by cancer cells regulates cancer progression and metastasis in the tumor microenvironment (TME) remains largely unknown. In this study, inter-alpha-trypsin inhibitor heavy chain 2 (ITIH2), an HA-binding protein, was confirmed to be secreted from mesenchymal-like lung cancer cells when co-cultured with cancer-associated fibroblasts. ITIH2 expression is transcriptionally upregulated by the EMT-inducing transcription factor ZEB1, along with HA synthase 2 (HAS2), which positively correlates with ZEB1 expression. Depletion of ITIH2 and HAS2 reduced HA matrix formation and the migration and invasion of lung cancer cells. Furthermore, ZEB1 facilitates alternative splicing and isoform expression of CD44, an HA receptor, and CD44 knockdown suppresses the motility and invasiveness of lung cancer cells. Using a deep learning-based drug-target interaction algorithm, we identified an ITIH2 inhibitor (sincalide) that inhibited HA matrix formation and migration of lung cancer cells, preventing metastatic colonization of lung cancer cells in mouse models. These findings suggest that ZEB1 remodels the HA network in the TME through the regulation of ITIH2, HAS2, and CD44, presenting a strategy for targeting this network to suppress lung cancer progression.